Literature DB >> 3161947

Regulation of mediator release from mouse bone marrow-derived mast cells by glucocorticoids.

J L Robin, D C Seldin, K F Austen, R A Lewis.   

Abstract

Mouse bone marrow-derived mast cells (BMMC), which were differentiated from their bone marrow precursors during 14 days of culture in the presence of a T cell lymphokine, were cultured in the absence or in the presence of 0.01 to 5 microM dexamethasone (DEX) for periods of 6 to 96 hr to assess the effects of steroid treatment on stimulus-dependent mediator release. Preincubation of the BMMC for 24 hr with DEX inhibited the subsequent immunoglobulin (Ig) E-dependent release of beta-hexosaminidase in a dose-dependent manner by up to 38% (mean, n = 7) at 1 microM DEX, and the decrease was statistically significant at DEX concentrations greater than or equal to 0.5 microM. DEX (1 microM) inhibited granule secretion from BMMC in a time-dependent manner; the decrease was statistically significant after a preincubation period of 6 hr, was maximal after preincubation times greater than or equal to 24 hr, and was reversible by 24 hr of incubation in medium lacking the steroid. Preincubation for 24 hr with DEX also inhibited the IgE-dependent biosynthesis and release of the immunoreactive leukotrienes (LT)C4 and LTB4 in a dose-dependent manner by up to 56% (n = 7) and 54% (n = 7), respectively, at 1 microM DEX, and the decrease was statistically significant for each product at DEX concentrations greater than or equal to 0.1 microM. In contrast, BMMC preincubated with DEX for 24 hr before sensitization and antigen challenge demonstrated a statistically significant increase in the release of immunoreactive prostaglandin (PG) D2 at DEX concentrations greater than or equal to 0.1 microM and a maximal enhancement of 188% (n = 3) at 1 microM DEX. The effect of 1 microM DEX on the enhancement of IgE-dependent PGD2 generation was significant after 6 hr, and was maximal by 72 hr. The inhibitory effects of DEX on the antigen-induced release of 5-lipoxygenase pathway products were confirmed by the physical measurements of 5-hydroxy-eicosatetraenoic acid (5-HETE) and LTC4, and by isotopic measurement of [3H]LTC4 after reverse-phase high performance liquid chromatography (RP-HPLC). As assessed by fluorescence cytofluorography of IgE-sensitized BMMC that were interacted with F(ab')2 rabbit anti-mouse epsilon and fluorescein isothiocyanate-labeled F(ab')2 goat anti-rabbit IgG-F(ab')2, the number of IgE-Fc receptors on the cell surface decreased by more than 55% after treatment for 24 hr with 1 microM DEX.+

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3161947

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  12 in total

1.  Effect of GR32191, a potent thromboxane receptor antagonist, on exercise induced bronchoconstriction in asthma.

Authors:  J P Finnerty; O P Twentyman; A Harris; J B Palmer; S T Holgate
Journal:  Thorax       Date:  1991-03       Impact factor: 9.139

2.  Rapid non-genomic effects of hydrocortisone on rat mast cells.

Authors:  A Dukhanin; V Nikitin; G Engalicheva; P Sergeev
Journal:  Inflamm Res       Date:  1996-03       Impact factor: 4.575

3.  Cultured human bone marrow-derived mast cells, their similarities to cultured murine E-mast cells.

Authors:  L Gilead; E Rahamim; I Ziv; R Or; E Razin
Journal:  Immunology       Date:  1988-04       Impact factor: 7.397

4.  Immunology of allergic rhinitis, or a nose for treatment.

Authors:  V J Lund; D J Wright; R J Davies
Journal:  J R Soc Med       Date:  1986-10       Impact factor: 5.344

5.  Chondroitin sulphate inhibits connective tissue mast cells.

Authors:  T C Theoharides; P Patra; W Boucher; R Letourneau; D Kempuraj; G Chiang; S Jeudy; L Hesse; A Athanasiou
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

6.  Glucocorticoids inhibit prostaglandin synthesis not only at the level of phospholipase A2 but also at the level of cyclo-oxygenase/PGE isomerase.

Authors:  M Goppelt-Struebe; D Wolter; K Resch
Journal:  Br J Pharmacol       Date:  1989-12       Impact factor: 8.739

7.  Dexamethasone rapidly suppresses IL-33-stimulated mast cell function by blocking transcription factor activity.

Authors:  Anuya Paranjape; Oksana Chernushevich; Amina Abdul Qayum; Andrew J Spence; Marcela T Taruselli; Daniel Abebayehu; Brian O Barnstein; Jamie Josephine Avila McLeod; Bianca Baker; Gurjas S Bajaj; Alena P Chumanevich; Carole A Oskeritzian; John J Ryan
Journal:  J Leukoc Biol       Date:  2016-07-21       Impact factor: 4.962

8.  Differential regulation of mast cell cytokines by both dexamethasone and the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580.

Authors:  R D Koranteng; E J Swindle; B J Davis; R J Dearman; I Kimber; B F Flanagan; J W Coleman
Journal:  Clin Exp Immunol       Date:  2004-07       Impact factor: 4.330

9.  Effects of immunomodulators on airways hyperresponsiveness to adenosine induced in actively sensitised Brown Norway rats by exposure to allergen.

Authors:  Bruno Tigani; Jason P Hannon; Elisabeth Schaeublin; Lazzaro Mazzoni; John R Fozard
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2003-06-24       Impact factor: 3.000

10.  Dexamethasone inhibits the development of mast cells from dispersed human fetal liver cells cultured in the presence of recombinant human stem cell factor.

Authors:  A A Irani; G Nilsson; L K Ashman; L B Schwartz
Journal:  Immunology       Date:  1995-01       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.